[Asia Economy Reporter Jang Hyowon] Nexten Bio announced on the 24th that Rosbivo, its largest shareholder, is selecting a contract manufacturing organization (CMO) capable of microRNA (miRNA) contract production to accelerate preclinical trials.
The candidate contract manufacturing companies under consideration by Rosbivo are nucleic acid (DNA/RNA) technology specialists based in the United States and Germany, known to have experience producing siRNA and certified according to national standards.
Founded in the United States in 1987, IDT (Integrated DNA Technologies) is a company specializing in the manufacture of oligonucleotides and custom DNA required for biotechnology experiments. It has signed contracts to supply products to leading university laboratories in the U.S. and the Centers for Disease Control and Prevention (CDC).
Additionally, BioSpring GmbH is one of the world’s leading companies in nucleic acid synthesis technology development and production. Located in Germany, its headquarters have held cGMP (Current Good Manufacturing Practice) certification for over 12 years and have passed the U.S. FDA quality control inspections more than twice. Notably, BioSpring’s proprietary process facilities capable of producing DNA and RNA in kilogram quantities are another of its strengths.
A Nexten Bio official stated, “Among the many CMO companies certified by national standards, there are not many that can produce miRNA, but we will select the optimal company that can produce miRNA stably. We will do our best to ensure that the preclinical trials conducted by Rosbivo proceed successfully within the set timeframe.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
